SecBot SecBot
SECBOTREPLAY Home › Report › OPK

OPK · OPKO Health announced an amendment to its Nicoya Therapeutics…

OPKO Health, Inc. · PRESS-RELEASE filed Apr 30, 2026 at 08:30 ET

At the news

NEUTRALIMPACT 4/10

PRESS-RELEASE filed Apr 30, 2026 at 08:30 ET

OPKO Health announced an amendment to its Nicoya Therapeutics agreement, receiving a 15% equity stake in Nicoya in exchange for revised royalty/transfer pricing, while keeping the $115M milestone structure intact. The deal deepens strategic alignment for RAYALDEE commercialization in Greater China, where regulatory approvals are expected in 2027, but provides no immediate revenue or cash consideration.

  • OPKO received a 15% equity stake in Nicoya via Series A-2 Preferred Shares in two tranches.
  • Revised tiered royalty and transfer price schedule replaces prior terms; milestone payments up to $115M unchanged.
  • RAYALDEE approved in Macau; regulatory approvals in China and related territories expected in 2027.
  • No upfront cash payment or immediate revenue recognized from the amendment.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access